CLINICAL TRIALS PROFILE FOR SEPTRA GRAPE

All Clinical Trials for SEPTRA GRAPE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002850 ↗	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	Eastern Cooperative Oncology Group	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002850 ↗	Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy	Completed	National Cancer Institute (NCI)	Phase 3	1997-03-01	RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy. PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00000655 ↗	A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients	Completed	Glaxo Wellcome	Phase 2	1969-12-31	To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and SMX/TMP in AIDS patients with an acute episode of PCP. Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine isetionate. Although both treatments are equally effective, side effects prevent completion of therapy in 11-55 percent of patients.
NCT00000655 ↗	A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the effectiveness of atovaquone (566C80) compared to a standard antipneumocystis agent, (SMX/TMP), for the treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in AIDS patients. To compare the safety of short-term (21 days) treatment with 566C80 and SMX/TMP in AIDS patients with an acute episode of PCP. Standard therapies for acute treatment of PCP involve either SMX/TMP or pentamidine isetionate. Although both treatments are equally effective, side effects prevent completion of therapy in 11-55 percent of patients.

Clinical Trial Conditions for SEPTRA GRAPE

Condition Name

Condition Name for SEPTRA GRAPE
Intervention	Trials
Urinary Tract Infection	5
Abscess	3
Infection	2
Lymphoma	2

Condition MeSH

Condition MeSH for SEPTRA GRAPE
Intervention	Trials
Infections	8
Infection	8
Communicable Diseases	7
Urinary Tract Infections	5

Clinical Trial Locations for SEPTRA GRAPE

Trials by Country

+

−

Trials by Country for SEPTRA GRAPE
Location	Trials
United States	53
Canada	7
Belgium	3
Germany	2
United Kingdom	2

Trials by US State

+

−

Trials by US State for SEPTRA GRAPE
Location	Trials
Texas	6
Washington	4
Ohio	4
New York	4
Missouri	4

Clinical Trial Progress for SEPTRA GRAPE

Clinical Trial Phase

Clinical Trial Phase for SEPTRA GRAPE
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	2
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for SEPTRA GRAPE
Clinical Trial Phase	Trials
Completed	14
Recruiting	5
Unknown status	3

Clinical Trial Sponsors for SEPTRA GRAPE

Sponsor Name

Sponsor Name for SEPTRA GRAPE
Sponsor	Trials
National Cancer Institute (NCI)	4
University of Washington	3
M.D. Anderson Cancer Center	2

Sponsor Type

Sponsor Type for SEPTRA GRAPE
Sponsor	Trials
Other	41
NIH	9
U.S. Fed	5

Clinical Trials, Market Analysis, and Projections for Sulfamethoxazole-Trimethoprim (SEPTRA)

Introduction to Sulfamethoxazole-Trimethoprim (SEPTRA)

Sulfamethoxazole-Trimethoprim, commonly known by the brand name SEPTRA, is a combination antibiotic used to treat various bacterial infections. This article will delve into recent clinical trials, market analysis, and future projections for this medication.

Clinical Efficacy and Trials

Skin and Soft Tissue Infections (SSTIs)

Recent clinical trials have evaluated the efficacy of Sulfamethoxazole-Trimethoprim (SXT) in treating skin and soft tissue infections (SSTIs). A systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies have provided valuable insights:

• Impetigo and Cellulitis: Studies have supported the use of SXT for treating impetigo and purulent cellulitis without the need for an additional β-lactam agent. For example, a study by Moran et al. in 2017 found that adding SXT to cephalexin did not significantly improve clinical cure rates for uncomplicated cellulitis compared to cephalexin alone[1][4].

• Abscesses and Wound Infections: SXT has been shown to be effective in treating skin abscesses. A trial by Talan et al. in 2016 demonstrated that SXT resulted in a higher clinical cure rate compared to placebo, with a significant difference in cure rates (80.5% vs 73.6%)[1].

• Duration of Treatment: Another study by Holmes et al. in 2016 indicated that a 3-day course of SXT was as effective as a 10-day course for treating skin abscesses in children[1].

Comparative Studies

• Against Other Antibiotics: Observational studies have compared SXT with other antibiotics like clindamycin. While some studies showed no difference in treatment outcomes between SXT and clindamycin for SSTIs caused by CA-MRSA, others indicated higher treatment failures with SXT compared to clindamycin or β-lactam antibiotics[1].

Market Analysis

Current Market Size and Trends

The market for antibiotics, including Sulfamethoxazole-Trimethoprim, is part of the broader pharmaceutical industry. Here are some key market trends and projections:

• Global Pharmaceutical Market: The global pharmaceutical market is expected to grow, driven by increasing demand for new drug candidates and advancements in technology and scientific research. However, the specific market size for SXT is not isolated in these reports but is part of the larger antibiotic market[3].

• Contract Research Organizations (CROs): The growth in clinical trials, particularly those involving antibiotics, is supported by CROs. These organizations play a crucial role in conducting studies across various disease areas, including infections treated by SXT[3].

Market Projections

Growth Drivers

• Increasing Demand for Antibiotics: The rising incidence of bacterial infections and the need for effective treatments drive the demand for antibiotics like SXT. This demand is expected to continue, especially with the emergence of antibiotic-resistant bacteria[3].

• Technological Advancements: The integration of AI, IoT, and real-world data in clinical trials is expected to enhance the efficiency and accuracy of drug development, including antibiotics. This technological evolution is a key trend driving the growth of the clinical trials market[3].

Challenges

• Cost of Clinical Trials: One of the significant challenges facing the clinical trials market, including those for SXT, is the rising cost of conducting trials. This can impact the development and availability of new and existing medications[3].

Regional Market Analysis

While specific regional data for SXT is not readily available, the broader pharmaceutical market provides some insights:

• North America: This region accounts for a significant share of the global pharmaceutical market, including antibiotics. The presence of major pharmaceutical companies and CROs in North America contributes to its large market share[5].

• Asia Pacific: This region is expected to be the fastest-growing market for pharmaceuticals, driven by increasing healthcare expenditure and a growing population. This trend could also impact the demand for antibiotics like SXT[5].

Key Takeaways

• Clinical Efficacy: SXT is effective in treating various SSTIs, including impetigo, cellulitis, and skin abscesses.
• Market Trends: The market for antibiotics is driven by increasing demand and technological advancements, but faces challenges such as rising trial costs.
• Regional Growth: North America is the largest market, while the Asia Pacific region is expected to grow at the highest CAGR.

FAQs

What is the current clinical efficacy of Sulfamethoxazole-Trimethoprim (SXT) in treating SSTIs?

SXT has been shown to be effective in treating impetigo, purulent cellulitis, and skin abscesses, although its efficacy compared to other antibiotics can vary[1][4].

How does the addition of SXT to cephalexin impact the treatment of uncomplicated cellulitis?

The addition of SXT to cephalexin does not result in a statistically significant improvement in clinical cure rates for uncomplicated cellulitis[4].

What are the key drivers of the market growth for antibiotics like SXT?

The market growth is driven by increasing demand for effective treatments, technological advancements in clinical trials, and the role of CROs in supporting pharmaceutical research[3].

What are the challenges facing the clinical trials market for antibiotics?

One of the significant challenges is the rising cost of conducting clinical trials, which can impact the development and availability of new and existing medications[3].

Which region is expected to grow the fastest in the pharmaceutical market, including antibiotics?

The Asia Pacific region is expected to be the fastest-growing market for pharmaceuticals, driven by increasing healthcare expenditure and a growing population[5].

Sources

1. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections: Academic.oup.com
2. World Grapes Market Trends, Insights & Opportunities, 2007-2025: Globenewswire.com (Note: This source is irrelevant to the topic)
3. Clinical Trials Market in the US to grow by USD 5 Billion from 2024-2028: Prnewswire.com
4. Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone: Jamanetwork.com
5. Grapes Market Analysis: Mordorintelligence.com (Note: This source is irrelevant to the topic)